The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery.

Autor: Kouvelos GN; Department of Surgery-Vascular Surgery Unit, School of Medicine, University of Ioannina, Ioannina, Greece., Arnaoutoglou EM; Department of Anesthesiology, School of Medicine, University of Ioannina, Ioannina, Greece., Milionis HJ; Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece., Raikou VD; First Department of Internal Medicine, School of Medicine, University of Athens, Athens, Greece., Papa N; Department of Surgery-Vascular Surgery Unit, School of Medicine, University of Ioannina, Ioannina, Greece., Matsagkas MI; Department of Surgery-Vascular Surgery Unit, School of Medicine, University of Ioannina, Ioannina, Greece mimats@cc.uoi.gr milmats@gmail.com.
Jazyk: angličtina
Zdroj: Angiology [Angiology] 2015 Feb; Vol. 66 (2), pp. 128-35. Date of Electronic Publication: 2014 Jan 22.
DOI: 10.1177/0003319713519492
Abstrakt: We compared the effects of lipid lowering with rosuvastatin (RSV) monotherapy versus intensified treatment by combining RSV with ezetimibe (EZT) on kidney function in patients undergoing vascular surgery. Patients were randomly assigned to either 10 mg/d RSV (n = 136) or RSV 10 mg/d plus EZT 10 mg/d (RSV/EZT, n = 126). At 12 months, a similar decrease in estimated glomerular filtration rate (eGFR) was noted. Patients who achieved a low-density lipoprotein cholesterol (LDL-C) of <100 mg/dL had less eGFR decrease than those patients having an LDL-C limit of more than 100 mg/dL. There were no significant changes in the urinary total protein to creatinine ratio in either group. Significant microalbuminuria was evident in both the groups. Patients undergoing vascular surgery show deterioration in their renal function during the first year, despite statin therapy. Intensified lipid-lowering therapy by adding EZT does not appear to have any renoprotective effect.
(© The Author(s) 2014.)
Databáze: MEDLINE
Externí odkaz: